Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (DE:1YR)
:1YR
Earnings Data
Report Date
Aug 21, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.03Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -23.08%
|Next Earnings Date:Aug 21, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in test development and financial management, with successful analytical validation and a promising rights issue. However, challenges remain with increased cash burn, limited initial revenue, and regulatory hurdles. The company is optimistic about its strategic plans for 2025, particularly the U.S. launch.Company Guidance
In the Immunovia Q3 2024 earnings call, significant progress was reported on the development and validation of their next-generation pancreatic cancer test. The model-development study completed in Q3 showed promising results with 85% sensitivity and 98% specificity, outperforming the CA19-9 test by 20 percentage points in sensitivity. Analytical validation confirmed the precise measurement of biomarkers, leading to the clinical validation study, which includes over 1,000 samples. Financially, Immunovia reduced operating expenses by 20% to just over SEK 30 million and cut cash burn by 40% to SEK 21 million for the quarter. They raised SEK 52 million through a rights issue and aim to maintain a cash balance of SEK 54 million to support operations into 2025. Plans are underway to launch the test in the U.S. in the second half of 2025, supported by a strategic partner to drive adoption and prepare for reimbursement and commercialization efforts.Next-Generation Test Development Success
The next-generation test showed 85% sensitivity and 98% specificity in the model-development study, outperforming CA19-9 by 20 percentage points in sensitivity.
Analytical Validation Achievements
Completed analytical validation with strong technical performance, measuring target proteins accurately across various conditions.
Successful Rights Issue
Raised SEK 52 million, exceeding expectations with a 91% subscription level, well above the 50% guaranteed level.
Operational and Financial Efficiency
Reduced OpEx by 20% and cash burn by 40% compared to the previous year, driven by a significant decrease in headcount costs.
Strategic Partner Plans for U.S. Launch
Planning to launch the test in the U.S. market in the second half of 2025, with a focus on securing a strategic partner to drive adoption.
DE:1YR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:1YR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | €0.01 | €0.02 | +30.77% |
Feb 25, 2025 | €0.02 | €0.02 | 0.00% |
Nov 27, 2024 | €0.03 | €0.03 | 0.00% |
Aug 05, 2024 | €0.10 | €0.09 | -5.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immunovia AB (DE:1YR) report earnings?
Immunovia AB (DE:1YR) is schdueled to report earning on Aug 21, 2025, TBA Not Confirmed.
What is Immunovia AB (DE:1YR) earnings time?
Immunovia AB (DE:1YR) earnings time is at Aug 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Immunovia AB stock?
The P/E ratio of Immunovia AB is N/A.
What is DE:1YR EPS forecast?
Currently, no data Available